MAAT INDEX

CLAIM #20794 · DHR (DHR) · 2024Q3 earnings call · Oct 22, 2024 · due Dec 31, 2024

Tycho, we're still looking here to see how the fourth quarter plays out and to see whether we can see a pickup in the stimulus, particularly in China, while we do expect the developed markets to be stable along the lines that I just discussed for Q3.

Rainer Blair · CEO

PENDING
graded after results covering Dec 31, 2024 are reported

In context

, but that really hasn't translated into meaningful orders for us as customers continue to wait for those details. So -- and while they're waiting for those details, they tend to also delay perhaps the normal purchasing habits that they might have had. So the stimulus funding has yet to pick up here in the third quarter. Tycho Peterson: Okay. And then a follow-up. I know you don't want to talk about '25 yet, but if we look at kind of the run rate for guidance on life sciences that you're giving us for the fourth quarter, the Street is at 6% next year on life sciences. Is that realistic, kind of, given the run rate you're laying out for the fourth quarter? And then anything you can say on China bioprocess for next year? We've seen some of your peers talk down numbers as well? Rainer Blair: Tycho, we're still looking here to see how the fourth quarter plays out and to see whether we can see a pickup in the stimulus, particularly in China, while we do expect the developed markets to be stable along the lines that I just discussed for Q3. So we're looking to see how China's stimulus plays out here in Q4 before we can get to 2025 numbers. Now as it relates to bioprocessing, we continue to see there a low activity level, albeit stable, but at a lower level, and we expect that to take more time to play out here in the near term. Matt McGrew: Yeah, maybe just to kind of follow up, I think the comment on the China stimulus is for tools, Tycho, right, just kind of what we're seeing there for '25 overall. So that's kind of '25 overall for Danaher for tools, but for bioprocessing for '25, I think we've kind of talked about a gradual recovery here in '24 and that's pretty well played out like we thought. Like Rainer said, we do need to see sort of how Q4 plays out, but -- before we kind of give anything formal on '25. But that said

Verify independently

SEC filings for DHR · Claim quote is verbatim from the 2024Q3 earnings call.